Results 131 to 140 of about 6,571 (189)

Correction: Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity. [PDF]

Sci Rep
Samad A, Shahid S, Mansoor S, Afzal S, Javed M, Zidan A, Shoaib A, Jaber F, Iqbal S, Saad M, Mahmood S, Awwad NS, Ibrahium HA.   +12 more
europepmc   +1 more source

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). [PDF]

PLoS One
Xiong W, Li Y, Huang J, He G, Sun J.
europepmc   +1 more source

Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. [PDF]

BMC Pharmacol Toxicol
Hayakawa T, Akimoto H, Nagashima T, Minagawa K, Takahashi Y, Asai S.   +5 more
europepmc   +1 more source

Association Between DPPs-4 Inhibitors and Bullous Pemphigoid: Reporting Odds Ratio Analysis Using EudraVigilance Database. [PDF]

Pharmaceuticals (Basel)
Pedrero AC, Aldea-Perona A.
europepmc   +1 more source

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]

Pharmacoepidemiol Drug Saf
Aloke C, Adelusi OA, Onisuru OO, Iwuchukwu EA, Achilonu I.   +4 more
europepmc   +1 more source

Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. [PDF]

Cureus
Selvaraj V.
europepmc   +1 more source

CD26 as a potential therapeutic target for lung adenocarcinoma. [PDF]

Front Oncol
Jungraithmayr W, Ohm B, Haberecker M, Curioni-Fontecedro A, Janker F, Gil-Bazo I, Soltermann A, Kirschner M, Weder W, Opitz I, Jang JH.   +10 more
europepmc   +1 more source

A case series of vildagliptin-associated bullous pemphigoid - Rare side effect. [PDF]

Indian J Pharmacol
Shahi MK, Ashwin JV, Singh A, Gupta S, Surya K.   +4 more
europepmc   +1 more source

Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors. [PDF]

Eur J Med Res
Saber K, Ismail R, Bassyouni A, El-Shafee M, Hassan MH.   +4 more
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid in an Elderly Woman With Type 2 Diabetes Mellitus: A Case Report. [PDF]

Cureus
Roa Alvarez G, Shuchleib Cukiert M, Hernández Altamirano FR, Berumen Glinz C, Vega Memije ME.   +4 more
europepmc   +1 more source